26th Aug 2026 17:17
Daiichi Sankyo Co Ltd and AstraZeneca PLC - pharmaceutical companies based in Tokyo and Cambridge, respectively - The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway, generic name datopotamab deruxtecan, plus either AstraZeneca's rilvegostomig or Datroway monotherapy versus current standard of care as an adjuvant treatment. Patients under study are diagnosed with muscle-invasive urothelial cancer at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. Datroway was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca. The partners are also evaluating Datroway plus platinum-based chemotherapy compared to gemcitabine and platinum-based chemotherapy in patients with metastatic urothelial carcinoma following progression during or after treatment with enfortumab vedotin in combination with pembrolizumab in the TROPION-Urothelial03 phase 2/3 trial.
"Following the encouraging results in the urothelial cancer cohorts of the TROPION-PanTumor03 and TROPION-PanTumor01 trials, we are now evaluating the combination of Datroway and rilvegostomig in earlier lines of treatment for this disease. TROPION-Urothelial04 marks our second pivotal trial in urothelial cancer as we continue to identify different types of cancer where Datroway may contribute to improving outcomes for patients," says Abderrahmane Laadem, head, therapeutic area oncology development, Daiichi Sankyo.
Daiichi Sankyo current share price: JPY2,900.00, closed up 2.5% in Tokyo on Wednesday
12-month change: down 19%
AstraZeneca current share price: 12,234.00 pence, closed down 1.9% in London on Wednesday
12-month change: up 3.1%
By Aidan Lane, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca